Search Results

2 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco...
  2. CORESTA Congress, Quebec, 2014, Smoke Science/Product Technology Groups, ST 78

    Predictability of in vitro toxicological assessments of cigarettes: analysis of seven years of regulatory submissions to Canadian authorities

    BELUSHKIN M.(1); PIADÉ J-J.(1); CHAPMAN S.(2); FAZEKAS G.(2)
    (1) Philip Morris International R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Rothmans, Benson & Hedges Inc., Brampton, Ontario, Canada
    Canadian authorities have required the annual submission of a wealth of by-brand information about cigarettes – including analytical data for cut filler and mainstream smoke constituents, for more than a decade. In 2005, the reporting requirements...